Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 when administered for 24 or 48 weeks with peginterferon alfa 2a and ribavirin for the treatment of genotype-1 chronic hepatitis C infection.
Epistemonikos ID: 2939572de769fbde29d2488c410510bcba88a016
First added on: Mar 23, 2020